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Abstract 
Introduction 
Severe mental illness (SMI), Human immunodeficiency virus (HIV) infection and hazardous 
alcohol use are global epidemics. Each condition is independently associated with significant 
adverse health outcomes. The presence of two or more of these conditions in one individual 
may result in worse health outcomes. A key mediator of poor health outcomes are factors 
such as medication adherence. In resource-limited countries like South Africa, the impact of 
psycho-social factors may contribute further to worse health outcomes. These factors include 
poverty and unemployment; as well as gender. In South Africa, proportionately more women 
are infected with HIV than men; and they are also vulnerable to the problems of trauma and 
interpersonal violence. The main aim of this study was to investigate the prevalence of a 
triple co-morbidity of HIV infection and hazardous alcohol use in a female population living 
with a SMI at a community psychiatric clinic in Cape Town South Africa; and the impact of 
this triple comorbidity on medication adherence. Furthermore, we set out to identify 
demographic and clinical variables that are predictors of poor adherence to both psychotropic 
medication and ART where applicable.  
Methods 
We conducted a cross-sectional study of female patients presenting to Gugulethu psychiatric 
clinic over a ten-month period. Demographics and clinical variables were explored using the 
Alcohol Use Disorders Identification Test (AUDIT); the adapted Morisky Scale to Assess 
Adherence to Psychotropic Medications; and an adherence to HIV antiretroviral treatment 
self-assessment instrument. A descriptive analysis of the demographic and predictor variables 
was undertaken to explore the prevalence of concurrent HIV infection and hazardous alcohol 
use in out-patients with SMI; as well as to investigate whether co-morbidity is associated 
with poor levels of adherence to psychotropic medication, as well as antiretroviral treatment 
(ART) in HIV positive patients.  
Results 
We interviewed 127 patients, of whom 55 were HIV positive (43.3%). The overall prevalence 
of a triple comorbidity in this population was 7.9%. Only 20% within this triple comorbidity 
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group were adherent to their psychotropic medication. Out of the 10 participants with a triple 
comorbidity, only five were on ART. Of these 5 participants, only two were adherent. 
Individuals with hazardous alcohol use were less adherent to psychotropic medication 
compared to those without. The seven respondents in the dual diagnosis group (SMI and 
hazardous alcohol use) had the lowest overall psychotropic adherence levels compared to the 
other subgroups (0%). Furthermore, concurrent hazardous alcohol use predicted poorer levels 
of compliance to ART for those with HIV infection.  
Conclusion 
The presence of a triple diagnosis was not found to be a predictor of poorer medication 
adherence, compared to having one or two diagnoses. Nevertheless, there was evidence that 
concurrent hazardous drinking in SMI patients predicted poor compliance to both 
psychotropic and ART treatment regimens (for those living with HIV). These patients should 
be supported in future interventions to improve medication adherence and reduce hazardous 
drinking.  
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Chapter 1: Introduction and literature review 
 
Background 
 
SMI, HIV infection and alcohol abuse are global epidemics. Each are associated with 
significant adverse health outcomes. These disorders have complex relationships, such that 
each may be associated with the development or acquisition of others. Each disorder may 
also result in worsening of the other: alcohol may result in HIV acquisition or worsen SMI; 
HIV may result in SMI and aggravate alcohol abuse; and SMI may result in HIV 
acquisition and alcohol abuse.  
 
Devieux et al (2007) reported the following with regards to patients living with a SMI. The 
patients who had a history of sexual abuse; engaging in sexual activities while high on 
substances; and lower cannabis use were found to be the most significant predictors of HIV 
sexual risk behaviours (1). Regarding SMI and alcohol abuse; one narrative review article 
found that low physical activity; poor diet; smoking; alcohol and substance abuse; and risky 
sexual behaviour are common in individuals with SMI (2). A systematic review conducted by 
Collins et al showed that the prevalence of HIV infection amongst people living with a 
chronic and persistent mental illness was between 3.1 -22.9% (3). 
 
The presence of two or more of these abovementioned conditions in individuals is also 
known to occur. Where they occur in significant numbers in communities or sub-
populations, a “syndemic” may exist. A syndemic is defined as the “synergistic co-
occurrence of multiple epidemics and risk factors” (4). There is a paucity of data relating to 
the prevalence of syndemics in a South African context. The presence of two or more of 
these conditions may reasonably be thought to result in worse health outcomes, such as 
medication adherence, morbidity and even increased mortality. 
A Cape Town based study conducted by Pitpitan et al found that out of the psychosocial 
problems they had assessed via a syndemic approach, alcohol related problems were the 
only factors remaining in terms of an association with HIV risk behaviour once they had 
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controlled for the other psychosocial factors (4). Their study highlights the significant role 
that alcohol use contributes to risky sexual behaviour. This finding relates well to our 
research question which seeks to explore this correlation. 
 
Definition and categorization of mental disorders 
 
Mental illness is commonly categorised into common mental disorders and severe mental 
illness. Our study will be focusing on severe mental illness only. With regards to defining and 
quantifying severe and persistent mental disorders, there is limited consensus in the literature 
(5). A definition of SMI consists generally of three criteria: Firstly, a psychiatric diagnosis 
according to DSM or ICD criteria; secondly duration of illness that is more than two years 
and thirdly disability in functioning according to measures such as the new WHO 
International Classification of Functioning, Disability and Health [ICF] (6). Estimates of the 
prevalence of people with SMI are 0.7% of the adult population (7). The literature suggests 
that this prevalence estimate has remained consistent over time. For the purposes of our study 
SMI includes Schizophrenia; Bipolar disorder; Schizoaffective disorder and severe 
depression with and without psychosis. 
 
Dual Diagnosis 
 
In recent times the term ‘dual diagnosis’ has been established. It is a term that relates to the 
co-occurrence of severe mental illness and substance use in one individual. International 
studies such as the European Schizophrenia Cohort Study have shown a high lifetime rate of 
comorbid substance dependence. The highest rate was found in the United Kingdom at 35% 
(8). 
 
Globally mental illness and substance use disorders are currently the leading cause of 
disability, accounting for 23% of all YLD globally and 19% in Sub-Saharan Africa in 
2010 (9). Predictions suggest that considerable population growth and ageing will result in 
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an approximately 130% increase in the burden of mental and substance use disorders in 
Sub-Saharan Africa by the year 2050. This estimate is predicted to translate into 45 million 
Years living with disability (9). The WHO states that globally, an estimated 450 million 
people currently suffer from a mental illness. These statistics place mental disorders, 
worldwide as being amongst the leading causes of ill health and disability. Despite 
treatment being available, only one third of people living with a mental illness ever seek 
help (10). 
 
Saban and colleagues (2014) support the premise that comorbid substance use and mental 
disorders result in a major public health burden. These scholars also highlight that there is a 
scarcity of published South African data that relates to substance use and mental disorder 
comorbidity and its related contributing factors (11). 
Substance use trends in South Africa vary across the different regions. In the Western Cape 
Methamphetamine is the substance for which help is often sought. On a national level, 
alcohol is the substance which carries the greatest risk of harm (12) . Studies have 
consistently shown a migratory trend towards the more economically viable Provinces in 
South Africa, namely Gauteng Province and the Western Cape (13). These migratory patterns 
may thus be an additional factor to consider when assessing substance use trends in South 
Africa. Thus, although Methamphetamine use is highly prevalent in the Western Cape, 
alcohol use has far reaching public health implications and was thus chosen as the substance 
of focus for our study. 
  A local study conducted in the Western Cape found that methamphetamine use was low 
overall in their sample of African males and females across different drinking venues. The 
levels of use were even lower when men were compared to women within the sample. This 
finding suggests that within the female African population in the Western Cape, 
methamphetamine use levels are relatively low. Given that our study population consisted of 
African female participants, we decided to focus on alcohol use levels for the reasons stated 
above (14). 
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Gender matters 
 
Pitpitan et al (2013) highlight the greater vulnerabilities faced by women. Women are more 
likely to be confronted with: food insecurity intimate partner violence; compromised mental 
health; substance use and childhood abuse (4). Olley et al (2004) observed that there were 
gender related differences to finding out about an HIV positive diagnosis. Men were found to 
be more likely to engage in risky sexual behaviour and substance use including alcohol (15). 
One study found that women with both HIV and mental illness experienced unique 
vulnerabilities especially in relation to being exposed to traumatic life events (16). A study 
conducted in Zambia concluded that alcohol use and poverty were significant risk factors for 
contracting HIV/AIDS amongst the group of women that they interviewed (17).In Sub-
Saharan Africa 59% of people living with HIV/AIDS were women, across all age groups 
(18). 
 
The literature that the researcher reviewed indicated a relative paucity of studies that looked 
specifically at a female population. Considering this observation and in view of the 
abovementioned vulnerabilities, we chose to specifically look at only female respondents for 
our study. 
 
Cultural considerations 
 
Strebel et al highlight (2006) that the associations between gender roles; gender based 
violence and HIV risk are “complex and culturally specific” (19).Their research findings 
showed that there was still a prominence of gender roles related to male dominance. 
However, they also found that there was a shift towards women becoming more empowered. 
These shifts did not translate into an increase in the extent to which negotiations around sex 
practices occurred between the two genders. They also placed emphasis on the need for more 
focused attention on “the powerful and complex intersection of gender violence, substance 
abuse and HIV/AIDS” (19). Van de Water et al (2016) highlighted the need to move towards 
a more culturally aligned approach to making psychiatric diagnosis (20). The DSM 5 has also 
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captured this move by adding a Culture Formulation Interview as a part of their proposed 
approach to conducting a psychiatric assessment (20) . 
 
Researcher observations informing the study 
 
As a health care provider working at a local community clinic in Cape Town South Africa, 
the researcher made several casual observations. Firstly, there was an observation that there 
were a significant number of female patients in this outpatient setting as opposed to the 
inpatient setting in facilities such as Valkenberg psychiatric hospital acute wards. In such 
facilities, there was a predominance of male patients. Secondly it was noted that out of the 
eight to ten patients that were booked for the researcher each afternoon, at least one or two of 
these patients were also HIV positive. Thirdly it emerged that alcohol use and abuse was 
common amongst the patients presenting to Gugulethu psychiatric clinic. 
 
This led the researcher to consider the plausibility of whether in general, a significant 
proportion of the female patients attending this clinic were suffering from a “triple 
diagnosis”. The researcher became increasingly interested in finding out what proportion of 
these female patients had a mental illness in combination with a diagnosis of HIV and 
significant alcohol use and abuse. What was also striking amongst these patients was that 
their condition was also coupled with high levels of poverty, unemployment and psychosocial 
distress. The researcher was interested in assessing whether social and economic factors had 
an impact on the likelihood of a triple diagnosis. 
 
Significant vulnerabilities were apparent in the majority of the female patients at Gugulethu 
clinic. A lot of time during the interview was spent discussing the patient’s life stressors 
which often revolved around physical, emotional and other forms of abuse either from the 
spouse or their own children. There was also a lot of discussion related to unemployment and 
poverty. Linked to these factors was the apparent inaccessibility to a disability grant and 
other social grants for those who were most in need and were eligible for such benefits. 
Substance abuse and its repercussions was also a prominent feature during consultations. 
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Triple diagnosis - Gap in the research 
For the purposes of this study, ‘triple comorbidity’ refers to the co-occurrence of mental 
illness, substance abuse, particularly alcohol abuse and HIV infection. The researcher of this 
study is unaware of any study, which investigates the prevalence and correlates of a triple 
diagnosis in a South African or Sub-Saharan African context. The study by Klinkenberg and 
Sacks (2004) that was conducted in the United States of America Missouri was a non- South 
African study that addressed the concept of a ‘triple comorbidity’(16). There is an even more 
pronounced scarcity of data conducted in women in South Africa. 
 
Ours is a resource-constrained setting and this group of patients represents a particularly 
vulnerable population with substantial needs and exposure to significant levels of 
stigmatisation. A South African study by Egbe et al (2014) added to the growing literature 
that indicates “how stigma and discrimination impacts negatively on the mental health of 
service users and marginalizes them from society as it inhibits their capacity to lead normal 
lives” (21).It is for these reasons that we set out to conduct research that would expand on the 
knowledge we have and gain insights into the factors that characterise the conditions of 
women living with a mental illness and other related comorbidities. 
 
Theoretical model of HIV risk behaviour among adults with SMI  
 
 
 
 
 
 
 
 
Psychiatric 
illness 
Cognitive 
Behavioural 
factors 
Childhood 
abuse 
HIV Risk behaviour 
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Figure 1. Theoretical model of HIV risk behaviour among adults with SMI. Solid lines 
represent associations between multiple domains of influence and sexual risk as identified 
in the study by Meade and Sikkema (2005). Dashed lines represent associations that have 
been reported in other studies. Dotted lines represent hypothetical associations that still 
need to be examined (22). 
 
This theoretical model was developed as a component of a systematic review conducted by 
Meade and Sikkema. Their main area of focus was HIV risk behaviour in adults living with a 
SMI, and its associations. The model shows that substance abuse and psychiatric illness are 
both associated with increased HIV risk behaviour. A concerning conclusion from this review 
was the finding that many of the sexually active adults with SMI engaged in risky sexual 
behaviours. It is important that we gain insights into the reasons why this group of patients is 
particularly at risk for HIV infection. From this knowledge, appropriate interventions can 
then be proposed and implemented. 
 
There is a less robust, bidirectional association between psychiatric illness and substance 
abuse. We propose that another element that would have implications for this model is 
medication adherence. We would put forward that medication adherence is a form of ‘risky 
behaviour’. Poor adherence to psychiatric medication may directly and indirectly impact on 
HIV risk behaviour. Poorly adherent people may relapse and become sexually disinhibited 
and more likely to engage in risky sexual practices as a part of their illness episode.  We 
thus envisage a downward spiral of people living with an SMI, not being compliant on 
their medication; leading to an episode of mental illness. Such an episode being 
exacerbated or even triggered by concurrent substance use and abuse with the result of an 
increase in HIV sexual risk behaviour. 
 
In this review, women were found to be more likely to have unprotected sex than their 
male counterparts. This finding is in keeping with National South African HIV statistics 
Social 
Relationships 
Substance Use 
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which have demonstrated that there are more women who are testing HIV positive than 
men in our South African context (23). The outcomes of this review clearly illustrate that 
psychiatric illness; substance abuse; childhood abuse and cognitive behavioural factors are 
strongly associated with HIV risk behaviour. This has far reaching implications for both 
the affected individual, his/her family and the public health system in its entirety. 
 
Literature review 
 
The existing literature was searched for studies on clinic populations, where the presence 
of triple co-morbidity was established, together with the health outcome of medication 
adherence. PUBMED was searched using the following terms: mental illness; mental 
health; mental disorders; HIV; Human immunodeficiency virus; alcohol abuse; alcohol use 
disorder; substance abuse; outpatient clinic. Each term was searched separately and at the 
end the different search term results were combined using the advanced search option 
within PUBMED.  
 
The following filters were applied: female; studies conducted less than five years ago; and 
adult population. There were 91 papers that were retrieved. The title and abstracts were 
reviewed for inclusion, using the following criteria: (i) the study used clear diagnostic or 
valid measures of SMI and alcohol abuse, and these were reported; (ii) the study 
established HIV sero-status; (iii) the study reported on self- or objective measures of 
medication adherence (iv) The study reported on quality of life related factors. Studies of 
children, persons older than 65, and in-patient populations were not included. After 
applying our inclusion and exclusion criteria, only five of the 91 studies were deemed 
appropriate and fitting for our literature review. Most of the studies were excluded for not 
meeting our criteria relating to measures of medication adherence. The included studies are 
presented in Table 1. 
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Table 1. Summary of the articles that met our inclusion criteria 
Author& 
date 
Place& setting Sample size & type Measures used Main findings Comments 
Peltzer 
K,2012(24) 
Nationwide 
(SA)outpatient 
1532 Male & 
female, probability 
sample 
AUDIT 
Social funct 
Health survey 
Outpatients in this study did not experience a 
reduced quality of life related to their alcohol 
use compared with other attenders. 
Surprising, one would have expected a 
reduced quality of life in alcohol 
dependent patients 
Yehia BR 
et al (25) 
Philadelphia, 
urban clinics 
51 male & female, 
purposive sampling 
Semi structured 
interviews 
Patients not retained in care faced more 
barriers. Developing care models where social 
and financial barriers are addressed, mental 
health and substance abuse treatment is 
integrated, and patient-friendly services are 
offered is important to keeping HIV-infected 
individuals engaged in care. 
This study emphasised the need and 
importance of more integrated models 
of care to adequately manage PLWHA 
who have a mental illness and 
substance use problem. 
Mutabazi-
Mwesigire 
D,2013 (26) 
Uganda, OPD 
setting 
1274 males & 
females, random 
selection 
Medical 
Outcomes 
Study (MOS-
HIV) Health 
Survey &Globa
l Person 
Generated 
Index (GPGI) 
 Regardless of treatment status, PLHIV with 
depression or low education level 
and female gender were at risk of having a 
poor quality of life. 
Study findings point towards the 
increased vulnerability that female 
patients have. 
Marx KA et 
al 2011 (27) 
Philadelphia,3 
urban clinics 
212 male & female, 
random sample 
Chart review In the binary model, those with a history 
of substance use were about half as likely to be 
retained (OR 0.52, 95% CI 0.29-0.94) and 
Substance use emerges as a predictor 
of poor retention to ARV treatment. 
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those with an AIDS diagnosis were more than 
twice as likely to be retained (OR 2.18, 95% CI 
1.17-4.09). 
 
Murphy K 
et al 2011 
(28) 
California, two 
county HIV 
clinics 
49 male & 
female.ID via 
Computerised 
problem lists 
Clinician 
questionnaire 
51% of whom achieved an 
undetectable HIV viral load. These patients 
tended to have less drug use, more ongoing 
psychiatric visits and were more apt to take 
psychiatric medicines. A surprising finding 
was that many patients were successful 
with HIV treatment despite substance abuse, 
uncontrolled psychiatric symptoms, and lack of 
psychiatric care. 
It was an nteresting finding that 
missing clinic appointments had little 
influence on treatment outcomes. 
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It was noted that none of the studies reported on the prevalence of a triple comorbidity. 
This is mainly because the prevalence of a triple comorbidity was not the primary outcome 
measure for the abovementioned five studies. In essence, no study has been done up until 
now that looks at the prevalence of a triple comorbidity of HIV, SMI and alcohol abuse in 
a South African context. One of the studies reported an overall depression prevalence of 
33% within their cohort of PLHIV, a figure which is in keeping with other similar studies 
(26).This figure highlights how common psychiatric comorbidity is in PLHIV. This same 
study quotes comorbid depression ranges between 30% and 53%. Although this study is 
commenting on one psychiatric disorder, the literature does support the notion that PLHIV 
have a higher prevalence of psychiatric comorbidity and vice versa. It has been estimated 
for example, that the prevalence of HIV infection in the SMI population in the United 
States of America ranges from 3.1 to 22.9% (29).  
 
Regarding key health outcomes, two of the studies looked at quality of life as an outcome 
measure. Interestingly the study by Mutabazi-Mwesigire D. Et al (2013) found that PLHIV 
who also had comorbid depression or low education level and female gender were at higher 
risk of having a poor quality of life. They also concluded that PLHIV who were on 
antiretroviral treatment experienced greater quality of life. This finding holds relevance for 
our study. We are specifically conducting our study amongst female participants as they 
have been shown to have greater vulnerabilities than their male counterparts. Our study is 
also looking specifically at medication adherence. Based on our findings, we can begin to 
make inferences about the likely impact of poor versus good adherence on overall quality 
of life. The study by Peltzer and Pengpid (2012) found no reported reduced quality of life 
in alcohol dependent individuals. It is important to note though that these individuals did 
not have a triple comorbidity. This study was looking at alcohol using participants as their 
primary interest group in a general outpatient setting. On the other hand, alcohol 
dependence was found to be associated with compromised physical and mental health (24). 
This study reiterates the deleterious effect that harmful alcohol use has on the individual. 
This includes amongst other factors, an increase in physical and psychiatric comorbidities. 
 
The findings by Murphy K et al were surprising in that missing clinic appointments was 
found to have little impact on treatment outcomes. One would have deduced that poor 
clinical attendance correlated with poor medication adherence and subsequently poor 
treatment outcomes (28). 
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Common barriers to care that were reported by a group of HIV positive participants 
included the following: dealing with other life priorities such as looking after children; 
being physically unwell and feeling depressed (25). This is relevant to our study which 
looks at women only because women are often the ones who are unequally tasked with the 
responsibility of rearing children. Studies have also consistently shown that women have 
higher rates of depression than men with  a ratio of 2:1 (30). 
 
With regards to areas needing further research, the studies in general highlighted the need 
for increased HIV testing for patients with a severe mental illness (28).They also 
emphasised the importance of developing more integrated models of care to address some 
of the barriers that this patient group experience. 
 
The consensus from the above studies is that people living with any one of the three disorders 
we are investigating (SMI; HIV; harmful alcohol use) face greater vulnerabilities. These 
vulnerabilities result in poorer outcomes in measures such as quality of life assessments. 
Stigma is another important aspect that has been found to correlate with reduced quality of 
life amongst people living with an SMI such as schizophrenia (31).Medication adherence is 
important with regards to all three disorders. Being on ART improves health related 
outcomes and adherence to psychiatric medication is likely to also result in better health 
outcomes. Assessing levels of adherence amongst triply affected individuals versus dual 
diagnosis and single diagnosis participants is thus vital to assist in the appropriate planning 
and allocation of health care resources.  
 
Aims and objectives 
 
The main aim of this study was to investigate the prevalence of a triple co-morbidity of HIV 
infection and alcohol abuse in a female population living with a SMI at a community 
psychiatric clinic in Cape Town South Africa; and their impact on medication adherence. The 
presence of potential contributing variables, such as psycho-social needs in a resource limited 
setting was also explored. 
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Tables and figures             
Table 1 Group comparison of demographic and clinical variables in patients with SMI 
 HIV+/SU+  
(N = 10) 
HIV+/SU-  
(N = 45) 
HIV-/SU+ 
 (N = 7) 
HIV-/SU-  
(N = 65) 
Test 
Fisher exact 
Demographics: total nr 
with % in brackets 
 
Age 37.70 (6.67) 43.29 (9.64) 40.71 (11.67) 44.35 (10.12) Chisq = 5.847, df = 3, p = 0.120  
Education  
(% completing high school) 
0 (0%) 10 (22.2%) 1 (14.29%) 16 (24.62%) Chisq = 3.365, df = 3, p = 0.339 
P = 0.376 
Income (% > R2000 per 
month) 
2 (20%) 20 (44.44%) 2 (28.57%) 31 (47.69%) Chisq = 3.364, df = 3, p = 0.339 
P = 0.362 
Stable relationship (%) 8 (80%) 22 (48.89%) 6 (85.71%) 25 (38.46%) Chisq = 10.475, df = 3, p = 0.015 P = 0.014 
Has children (%) 10 (100%) 39 (86.67%) 6 (85.71%) 50 (76.92%) Chisq = 4.143, df = 3, p = 0.246 P = 0.270 
% employed or in school 
(full/part-time) 
1 (10%) 7 (15.56%) 1 (14.29%) 8 (12.31%) Chisq = 0.352, df = 3, p-value = 0.95 
P = 0.966 
Clinical history: Total nr 
with % in brackets 
 
Multiple admissions 5 (50.00%) 16 (35.56%) 1 (14.29%) 26 (40.00%) 
Chisq = 2.509, df = 3, p-value = 
0.474 
P = 0.508 
Psychotropic med. adherence 
(%) 
2 (20%) 20 (45.46%) 0 (0%) 35 (54.10%) Chisq = 7.655, df = 3, p = 0.054 
p = 0.045 
ARV adherence (100%) 40.00 (2/5) 88.46 (23/26) NA NA Chisq = 6.31, df = 1, p = 0.012 P = 0.038 
Not on ARVs (%) 5 (50.00%) 19 (42.20%) NA NA Chisq = 0.201, df = 1, p = 0.654 P = 0.733 
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Table 2 Association of demographic & clinical variables with psychotropic adherence 
 Adherent  
(N = 50) 
Non-adherent  
(N = 72) 
Test 
Age 43.70 (10.43) 42.83 (9.19) t = 0.474, p: 0.637 
Education  
(% completing high school) 
17 (34.8%) 9 (12.5%) Chisq=8.134, p=0.004 
Income (% greater than R2000 
per month) 
25 (50.00%) 27 (37.50%) 
Chisq=1.855, p=0.170 
 
Stable relationship (%) 16 (32%) 
 
43 (59.72%) 
 
Chisq =9.081, p=0.003 
Has children (%) 37 (74%) 65 (90.28%) Chisq =5.705, p=0,017 
% employed or in school 
(full/part time) 
8 (16%) 8 (11.1%) Chisq =0.619, p=0.431 
Multiple admissions (%) 20 (40%) 27 (37.2%) Chisq=0.353, p=0.552 
Hazardous drinking (%) 27 (54.29%) 64 (88.24%) Chisq =6.972, p=0.008 
100% ARV adherent*  15 (93.75%) 10 (75%) Odds ratio = 7.045, p = 0.083 
 
* Fishers exact test comparing proportion of 31 seropositive individuals in sample self-reporting 100% ARV  
  compliance by psychotropic medication compliance 
 
 
Table 3 Results of linear model of predictors of psychotropic adherence 
 Beta 
coefficient 
Std. Error Z value 
Odds ratio P value 
Hazardous drinking -1.2694      0.8149   -1.558    0.284 0.119 
Education (Grade 12 
+ tertiary) 
1.1998      0.5106    2.350    
3.319 0.019 
Stable relationship -1.0112      0.4288   -2.358    0.364 0.018 
Has children -0.6322     0.5606   -1.128    0.531 0.260 
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Abstract 
Introduction 
Severe mental illness (SMI), Human immunodeficiency virus (HIV) infection and hazardous 
alcohol use are global epidemics. Each condition is independently associated with significant 
adverse health outcomes. The presence of two or more of these conditions in one individual 
may result in worse health outcomes. A key mediator of poor health outcomes are factors 
such as medication adherence. In resource-limited countries like South Africa, the impact of 
psycho-social factors may contribute further to worse health outcomes. These factors include 
poverty and unemployment; as well as gender. In South Africa, proportionately more women 
are infected with HIV than men; and they are also vulnerable to the problems of trauma and 
interpersonal violence. The main aim of this study was to investigate the prevalence of a 
triple co-morbidity of HIV infection and hazardous alcohol use in a female population living 
with a SMI at a community psychiatric clinic in Cape Town South Africa; and the impact of 
this triple comorbidity on medication adherence. Furthermore, we set out to identify 
demographic and clinical variables that are predictors of poor adherence to both psychotropic 
medication and ART where applicable.  
 
Methods 
We conducted a cross-sectional study of female patients presenting to Gugulethu psychiatric 
clinic over a ten-month period. Demographics and clinical variables were explored using the 
Alcohol Use Disorders Identification Test (AUDIT); the adapted Morisky Scale to Assess 
Adherence to Psychotropic Medications; and an adherence to HIV antiretroviral treatment 
self-assessment instrument. A descriptive analysis of the demographic and predictor variables 
was undertaken to explore the prevalence of concurrent HIV infection and hazardous alcohol 
use in out-patients with SMI; as well as to investigate whether co-morbidity is associated 
with poor levels of adherence to psychotropic medication, as well as antiretroviral treatment 
(ART) in HIV positive patients.  
 
Results 
We interviewed 127 patients, of whom 55 were HIV positive (43.3%). The overall prevalence 
of a triple comorbidity in this population was 7.9%. Only 20% within this triple comorbidity 
group were adherent to their psychotropic medication. Out of the 10 participants with a triple 
comorbidity, only five were on ART. Of these 5 participants, only two were adherent. 
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Individuals with hazardous alcohol use were less adherent to psychotropic medication 
compared to those without. The seven respondents in the dual diagnosis group (SMI and 
hazardous alcohol use) had the lowest overall psychotropic adherence levels compared to the 
other subgroups (0%). Furthermore, concurrent hazardous alcohol use predicted poorer levels 
of compliance to ART for those with HIV infection.  
 
Conclusion 
The presence of a triple diagnosis was not found to be a predictor of poorer medication 
adherence, compared to having one or two diagnoses. Nevertheless, there was evidence that 
concurrent hazardous drinking in SMI patients predicted poor compliance to both 
psychotropic and ART treatment regimens (for those living with HIV). These patients should 
be supported in future interventions to improve medication adherence and reduce hazardous 
drinking.  
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Introduction  
 
Sub-Saharan Africa is plagued by several converging public health challenges. These include 
the HIV and tuberculosis epidemics, and a significantly high burden of morbidity and 
mortality resulting from violence and injury. There is also a significant proportion of the 
population that has chronic or non-communicable diseases (1). Mental health related 
disorders are a growing public health concern; linked to this is the ongoing problem of 
substance use and abuse in South Africa (SA). In addition to these challenges, South Africa 
has disproportionately higher levels of maternal, neonatal, and child mortality when 
compared to countries with larger population numbers and fewer resources (2). 
 
Severe versus common mental disorders 
Mental disorders are commonly categorised into common mental disorders and severe mental 
illness. This study will be focusing on severe mental illness (SMI) only. There is limited 
consensus within the literature with regards to defining and quantifying severe and persistent 
mental disorders (3). A definition of SMI consists generally of three criteria: firstly, a 
psychiatric diagnosis according to DSM or ICD criteria; secondly duration of illness that is 
more than two years and thirdly disability in functioning according to measures such as the 
new World Health Organisation (WHO) International Classification of Functioning, 
Disability and Health [ICF] (4). Global estimates of the prevalence of people with SMI are 
0.7% of the adult population (3). The literature suggests that this prevalence estimate has 
remained consistent over time. For the purposes of our study SMI includes Schizophrenia; 
Bipolar disorder; Schizoaffective disorder and severe depression with and without psychosis. 
 
HIV 
The WHO reports that 63% of all HIV-positive adults and children globally are found within 
Sub-Saharan Africa. This region encompasses 24.7 million adults who are infected with the 
virus (5). The national HIV prevalence, Incidence and Behaviour Survey of 2012 estimated 
that the HIV prevalence in South Africa increased from 10.6% in 2008 to 12.2% in 2012 (6). 
A concerning statistic found by this same survey is that the highest incidence of HIV 
infection is found in African females between the ages of 20 and 35 years (6) . There are a 
few theories with regards to explaining how and why the prevalence has continued to 
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increase. There are also factors that are making young African females particularly 
vulnerable to HIV.  
 
 
 
Gender matters 
Pitpitan and colleagues (2013) highlight the greater vulnerabilities faced by women. In this 
regard, women are more likely to be confronted with: food insecurity intimate partner 
violence; compromised mental health; substance use and a history of childhood abuse (7). 
The WHO reported that in Sub-Saharan Africa 59% of people living with HIV/AIDS are 
women, across all age groups (5). In a South African context, research has shown that gender 
power imbalances in relationships and intimate partner violence places women at an 
increased risk of HIV infection (8). The literature that the researcher reviewed indicated a 
relative paucity of studies that looked specifically at a female population. Considering this 
observation and in view of the above-mentioned vulnerabilities, we chose to specifically 
assess only female respondents for our study. 
 
Alcohol use 
A South African national survey conducted in 2011, reported that 9% of their study 
population met the criteria for hazardous alcohol use (9). Hazardous drinking is defined as: “a 
quantity or pattern of alcohol consumption that places patients at risk for adverse health 
events, while harmful drinking is defined as alcohol consumption that results in adverse 
events (eg, physical or psychological harm)” (10). This survey also reported that 41.5% of the 
men and 17.1% of the women within this study reported current alcohol use (9) .The survey 
also noted an increase in patterns of binge drinking and harmful alcohol use over a three-year 
period (2005 -2008). A randomised controlled trial conducted within a general outpatient 
population at a South African Academic Hospital, noted that 27.6% of their participants met 
the AUDIT criteria for harmful alcohol use (11). The AUDIT cut off score associated with a 
diagnosis of an alcohol use disorder (AUD) is eight and above (10).  
 
Kader et al conducted a South African study in an HIV positive outpatient population. They 
noted that 37% of their participants reported harmful or hazardous drinking (12). This trend 
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has been found in other non-South African studies as well. This group of participants were 
also found to be less likely to be on ART (12). 
 
Co-morbid disorders 
SMI, HIV infection and alcohol abuse are global epidemics. Each of these conditions is 
associated with significant adverse health outcomes. These disorders have complex 
relationships, such that each may be associated with the development or acquisition of others. 
Each disorder may also result in worsening of the other in the following manner: behavioural 
changes associated with heavy alcohol intake may result in HIV acquisition, or worsened 
SMI; HIV may result in SMI and aggravate alcohol abuse, and SMI may result in HIV 
acquisition and alcohol abuse. The presence of two or more of these abovementioned 
conditions in individuals is also known to occur. Where they occur in significant numbers in 
communities or sub-populations, a ‘syndemic’ may exist. A syndemic is defined as the 
“synergistic co-occurrence of multiple epidemics and risk factors” (7). There is a general 
paucity of data relating to the prevalence of syndemics in a South African context. The 
presence of two or more of these conditions may reasonably be thought to result in worse 
health outcomes, such as medication adherence, morbidity and even increased mortality. 
Devieux and colleagues (2007) conducted a study amongst a range of individuals with SMI. 
They set out to determine the most significant predictors of HIV sexual risk behaviours 
within this population. Their findings showed that a history of sexual abuse; engaging in 
sexual activities while high on substances; and lower cannabis use were the most significant 
predictors (13). Regarding SMI and alcohol abuse, one narrative review article found that low 
physical activity; poor diet; smoking; substance abuse and risky sexual behaviour are 
common in individuals with SMI (14). 
 
Implications of co-morbidity 
Each of these disorders on their own has significant implications for the affected individuals. 
Having all three in one individual is thus likely to have a compounded deleterious effect on a 
person’s health-related outcomes. Saban and colleagues (2014) support the premise that 
comorbid substance use and mental disorders result in a major public health burden. These 
scholars also highlight the fact that there is a scarcity of published South African data that 
relates to substance use and mental disorder comorbidity and its related contributing factors 
(15). 
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Another implication which forms the basis of this study is how these co-occurring disorders 
may adversely impact on adherence to both psychotropic and where applicable, antiretroviral 
therapy (ART). Kader et al (2015) conducted an outpatient clinic-based study in Cape Town 
which concluded that harmful alcohol use was a statistically significant predictor of poor 
ART adherence. This was in terms of both missing doses and stopping ARTs completely 
(16). A cohort study of HIV positive participants, conducted by Dewing and colleagues 
(2015) highlighted that a high percentage of their participants screened positive for either 
substance abuse or a mental disorder. Both substance abuse and screening positive for a 
mental disorder were amongst the factors which were found to be significantly associated 
with non-adherence to ART (17). 
 
The South African stress and health study found that out of all the respondents who received 
any mental health treatment in the preceding 12 months, 54% became non-adherent to their 
treatment regimen. The following demographic factors were not found to be predictors of 
non-adherence to treatment: age; sex; marital status; education and income. The existence of 
a substance use disorder was associated with higher odds (OR=3.7) (p< 0.05) of dropping out 
of treatment (18). 
 
Triple comorbidity 
For the purposes of this study, ‘triple comorbidity’ refers to the co-occurrence of severe 
mental illness, hazardous drinking and HIV infection in an individual. The researcher is 
unaware of any study which investigates the prevalence and correlates of a triple diagnosis or 
diagnosis in a South African context. A literature review conducted  by Klinkenberg and 
Sacks in the United States of America Missouri ,was one of the few articles we found that 
addressed the concept of a ‘triple diagnosis’(19).These scholars highlighted that within a 
group of people living with a mental illness, 20% to 50% will have a comorbid substance use 
disorder. Conversely, 50% to 75% of people with a substance use disorder meet criteria for a 
psychiatric disorder. The authors go further to suggest that co-occurring disorders (substance 
use and a mental disorder), may be more prevalent in women living with HIV than their HIV 
infected male counterparts. Triply diagnosed individuals are reported to have complex needs 
which pose significant clinical implications (19). Globally, there is a pronounced scarcity of 
data conducted solely in women and this scarcity is also apparent in South Africa. 
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The literature we reviewed points towards a South African national prevalence of alcohol use 
that is at 9.2%. We used the National HIV prevalence of 12.2% as a part of our calculation. 
South Africa’s national population currently stands at an estimated 54 million people (20), 
females constitute 51% of this estimate (27.64 million). Global estimates of SMI in the 
general population are approximately 0.7% (3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The above figure is a schematic representation of the three conditions that are the focus of our 
study. Our area of interest is the square in the middle, which represents the area where all 
three conditions overlap. The figures are based on the estimated national population of South 
Africa which currently stands at 54 million people (20). As a means of further 
contextualizing our findings, we looked at the specific prevalence estimates within the 
Western Cape. The prevalence of HIV infection in the South African National HIV survey in 
2012 in the Western Cape province was 5% across both genders. Amongst women in the 
Western Cape, the prevalence of hazardous or harmful drinking (AUDIT score greater than or 
equal to 8) is 5.6% in women (9). There is no current literature that points towards the extent 
of this overlap. Our study set out to determine this area of overlap and thus quantify the 
extent of a triple comorbidity.  
 
 
 
  
 
Alcohol use: 9.2% 
= 4 968 000 
SMI: 0.7% 
= 378 000 
 
HIV: 12.2% 
= 6 588 000 
 
Triple comorbidity 
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Hypotheses 
We aim to explore the prevalence of the triple co-morbidity of HIV infection and hazardous 
alcohol use among female patients living with a SMI within the community psychiatric health 
services. We further aim to explore whether factors such as substance use and HIV infection 
separately predict poorer medication adherence in this group of patients. We postulate that 
their combination in the form of a triple diagnostic group will be particularly prognostic of 
poor levels of medication adherence. This includes adherence to both psychotropic 
medication and where applicable, ART. 
 
 
 
Implementation Objectives 
We plan to provide feedback to the management team at Gugulethu Community health care 
centre and similar clinic settings. Our aim is to also raise awareness amongst people living 
with a mental illness, regarding these three diagnoses and their implications for their overall 
health and wellbeing. 
 
Methods 
 
Study setting and procedures 
We conducted a cross-sectional, descriptive and analytical survey of female patients 
presenting to Gugulethu community psychiatric clinic. Data collection began in February 
2015 and was concluded in November 2015. Selection of participants was carried out using 
convenience sampling methods. Clinical attendees who were presenting for their routine 
follow-up visits were screened to see if they meet our inclusion criteria. This was done by the 
trained psychiatric nurse at the facility who usually follows up the patients on a monthly 
basis. The nurse assessed their mental status on the day, acutely impaired/unwell patients 
were not referred to the research assistant. The research assistant conducted further screening 
and assessment for suitability to participate in the study. We first conducted a pilot of the 
study amongst two participants to ascertain the time it would take to complete the 
administration of the questionnaires for each respondent.  
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Inclusion criteria comprised of all females over the age of eighteen years with a diagnosis of 
a SMI. A diagnosis of a SMI was confirmed via reviewing the folder information. The 
following participants were excluded from our study: male patients and everyone either under 
the age of eighteen or over the age of sixty years; patients who were actively psychotic and 
unable to provide informed consent; those with a primary diagnosis of dementia or 
intellectual disability; and patients who declined to participate. 
 
Our review of clinic records suggested that approximately 50 patients attend the Gugulethu 
Psychiatric clinic per day, from Monday to Thursday. Based on the South African national 
population statistics we estimated that approximately 50% of these patients will be female 
(20). Thus, out of the fifty daily attendees, an estimated 25 will be female. This rendered a 
maximum sample size of 25 (females) x 3 (data collection days per week) x 4 (weeks per 
month) x 5 (months) =1500. At the end of our data collection time, we had a total of 140 
completed questionnaires. 
 
Measures 
We included measures to capture demographic and clinical information, as well as some 
intended to clarify hazardous alcohol use and our outcome variable of interest, namely 
psychotropic and ART adherence. Measures were translated into IsiXhosa, the indigenous 
language spoken in the area and were administered by an IsiXhosa - speaking research 
assistant. These measures were put in place to reduce the potential for confusion in 
terminology and to enhance the robustness of the responses, and thus the findings of the 
study. The combination of questionnaires used in the study included the following: 
 
[1] Firstly, we compiled a demographic and social data questionnaire. This included basic 
demographic information such as age, marital status, education level and income. Information 
regarding the psychiatric diagnosis was also collected via the use of this questionnaire 
(Appendix 2). 
 
[2] Secondly, we used the (AUDIT) Alcohol Use Disorders Identification Test (Appendix 5): 
The Audit is an instrument constructed by the WHO from a cross-national study. It provides a 
“simple method of early detection of hazardous and harmful alcohol use in primary health 
care settings”(21) . Volk and colleagues (1997) demonstrated that the AUDIT provided an 
unbiased measure of risky alcohol drinking in a family practice centre (22). These two 
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questionnaires formed the basis for our predictor variables. We defined current hazardous 
drinking as an AUDIT score greater than or equal to 8.  
 
In terms of our outcome measure of psychotropic and or antiretroviral treatment adherence, 
we used the following questionnaires: 
 
 [3] Adherence to HIV antiretroviral treatment self-assessment instrument: (Appendix 3) 
Adapted from Machtinger EL, Bangsberg DR. (23). Non-adherence to ARVs in the study 
sample was defined by answering the Adherence self-assessment tool which rated adherence 
on a scale of 0 to 100%. Adherence was dichotomised into those who reported 100% 
adherence, with the other group containing those participants who were less than 100% 
adherent. 
  
[4] Adapted Morisky Scale to Assess Adherence to Psychotropic Medications (Appendix 4): 
The original scale was based on adherence to antihypertensive medication. Results indicated 
that the scale had both concurrent and predictive validity with regard to blood pressure 
control over a specific time frame (24). Non-adherence to psychotropic medication in the 
study sample was defined by answering four questions. Non-adherence was assessed in the 
HIV positive group (both alcohol using and non-alcohol users). 
 
HIV status and ARV treatment status were assessed via questions within the demographic 
questionnaire, and are therefore self-report measures. Although serological testing was not 
conducted by study personnel to determine HIV status, participant folders were reviewed to 
assess whether there was a documented previous HIV test result. 
 
Ethical considerations 
Ethics approval for the study was granted by the University of Cape Town’s Faculty of 
Health Sciences Human Research Ethics Committee (Appendix 7). Institutional approval was 
granted by the Facility manager at Gugulethu CHC (Appendix 6). All the participants were 
counselled about the purpose of the study and written consent was obtained (Appendix 1). 
The study was conducted in accordance with the Declaration of Helsinki ethical principles 
(25). 
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Data analysis 
R statistical computing platform (version 3.2.3) was used to conduct the analyses (26) . We 
calculated means/medians/numbers and percentages for demographic, and clinical variables. 
We compared four groups stratified by HIV and substance use status on these variables by 
means of non-parametric Kruskal-Wallis tests or chi-squared tests for continuous and 
categorical data, respectively. Exact tests were employed for comparisons of ARV adherence 
proportions in HIV positive patients, given the small sample size for this analysis. In 
addition, logistic regression models were conducted to test whether group differences in 
adherence to psychotropic medication was robust to demographic and clinical covariates that 
differed between the groups.   
 
We calculated a post hoc power estimate to detect a medium effect with the sample size that 
we have of 127. For a medium-sized difference in adherence rates, we would have a power 
estimate of 0.82. This means that if the test were to be repeated 100 times in different 
samples of this population, we would detect a medium or larger difference in adherence 
between the four groups at least 82% of the time. Chi squared power calculation: pwr. chisq. 
test (w=0.3, N=127, df=3, sig. level=0.05) 
 
Results 
 
We obtained 140 completed questionnaires that met our inclusion criteria. However, thirteen 
of these participants did not know their HIV status. These thirteen people were thus excluded, 
resulting in a total of 127 participants that formed the basis of our analysis. 
 
Our first objective was to explore the prevalence of a triple comorbidity and we had 
hypothesized that there would be a high prevalence of a triple comorbidity in this population. 
The overall prevalence of a triple comorbidity in this population was 10 out of the total of 
127 participants who knew their HIV status (7.9%). In other words, our findings showed that 
7.9% of our sample met the criteria for hazardous alcohol use and were also HIV positive, in 
the context of having SMI.  
 
The overall prevalence of a triple comorbidity in this population was 7.9%. The prevalence of 
HIV within our entire group of participants was 43.3%. The total prevalence of hazardous 
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alcohol use was found to be 13.4% across our entire sample of patients. The correlates of 
non-adherence were not the presence of a triple comorbidity as we had hypothesized. The 
individual correlates which were of statistical significant (p value < 0.05) were the following:  
hazardous drinking; level of education and relationship status. 
 
The second part of our research question was to determine the correlates of this triple 
comorbidity. Table 1 is a tabulated description of our findings. We divided our sample into 
four subgroups based on the number of comorbidities each participant met the criteria for. 
The first column (HIV+/SU+) represents our main group of interest, this is the triple 
comorbidity group. The mean age of the 10 women within this group was 37.70 years. None 
of these 10 participants had completed grade 12; and only 20% had a household income 
greater than R2000 per month (approximately 140 US dollars). The majority were in a stable 
relationship (80%) and all of them had children. Only 10% were employed or pursuing their 
studies, in other words one participant out of the total of ten was working or studying at the 
time of our study. In terms of clinical variables, 50% of these participants have had more than 
one admission to a psychiatric facility in their lifetime. Only 20% within this group were 
adherent to their psychotropic medication. Out of the 10 participants with a triple 
comorbidity, only five were on ART (50%). Of these 5 participants, only two were adherent 
to their ART. Good adherence was defined by self-reports of 100% adherence on the ARV 
adherence questionnaire and by a psychotropic medication related dichotomous answer 
questionnaire. 
 
The second group consisted of 45 individuals, consisting of women with a SMI who are HIV 
positive but not using alcohol in a hazardous manner (HIV+/SU-). The most significant 
finding within this group was the higher proportion of adherence to psychotropic medication 
(45.46%) when compared to the triple comorbidity group (20%). Adherence to ART was also 
markedly greater in this group (88.46%), when compared to the triple comorbidity group 
(40%). 
 
The third group is the classic ‘dual diagnosis’ group of women with a SMI, negative HIV 
status and hazardous alcohol use (HIV-/SU+). This was the smallest of the four sub-groups 
(n=7). Demographic variables within this group were generally comparable to the participants 
in the other three groups. Notably, 85.71% of participants within this group were in a stable 
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relationship. Psychotropic medication adherence was the lowest within this group when 
compared to the other three subgroups (14.29%).  
 
The last subgroup consists of the single diagnostic participants, i.e. those who only met the 
criteria for an SMI (HIV-/SU-). Demographic variables were generally comparable to the 
other three groups. Interestingly, this group had the lowest proportion of participants who 
were in a stable relationship when compared to the other three subgroups (38.4%). This group 
was found to have the highest proportion of psychotropic medication adherence (54.10%) 
when compared to the other three groups. 
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Table 2 Group comparison of demographic and clinical variables in patients with SMI 
 HIV+/SU+  
(N = 10) 
HIV+/SU-  
(N = 45) 
HIV-/SU+ 
 (N = 7) 
HIV-/SU-  
(N = 65) 
Test 
Fisher exact 
Demographics: total nr 
with % in brackets 
 
Age 37.70 (6.67) 43.29 (9.64) 40.71 (11.67) 44.35 (10.12) Chisq = 5.847, df = 3, p = 0.120  
Education  
(% completing high school) 
0 (0%) 10 (22.2%) 1 (14.29%) 16 (24.62%) Chisq = 3.365, df = 3, p = 0.339 
P = 0.376 
Income (% > R2000 per 
month) 
2 (20%) 20 (44.44%) 2 (28.57%) 31 (47.69%) Chisq = 3.364, df = 3, p = 0.339 
P = 0.362 
Stable relationship (%) 8 (80%) 22 (48.89%) 6 (85.71%) 25 (38.46%) Chisq = 10.475, df = 3, p = 0.015 P = 0.014 
Has children (%) 10 (100%) 39 (86.67%) 6 (85.71%) 50 (76.92%) Chisq = 4.143, df = 3, p = 0.246 P = 0.270 
% employed or in school 
(full/part-time) 
1 (10%) 7 (15.56%) 1 (14.29%) 8 (12.31%) Chisq = 0.352, df = 3, p-value = 0.95 
P = 0.966 
Clinical history: Total nr 
with % in brackets 
 
Multiple admissions 5 (50.00%) 16 (35.56%) 1 (14.29%) 26 (40.00%) 
Chisq = 2.509, df = 3, p-value = 
0.474 
P = 0.508 
Psychotropic med. adherence 
(%) 
2 (20%) 20 (45.46%) 0 (0%) 35 (54.10%) Chisq = 7.655, df = 3, p = 0.054 
p = 0.045 
ARV adherence (100%) 40.00 (2/5) 88.46 (23/26) NA NA Chisq = 6.31, df = 1, p = 0.012 P = 0.038 
Not on ARVs (%) 5 (50.00%) 19 (42.20%) NA NA Chisq = 0.201, df = 1, p = 0.654 P = 0.733 
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Non-adherence in the study sample was defined as patients either admitting that they had ever 
forgot to take their medications, that they were careless at times about taking their 
medication, that they sometimes stopped taking their medication when they felt better or 
when they felt worse. 
 
Five patients were excluded from the psychotropic medication comparisons (the four who 
were on depot or injectable treatment and one participant who was not receiving any 
psychotropic treatment). A non-parametric Kruskall-Wallis test was employed for continuous 
covariates. The number of individuals diagnosed with Schizoaffective disorder was too small 
(N = 3) for statistical analysis. 
 
 
Figure 1. Bar graph comparing the four different groups by psychotropic medication 
compliance 
 
 
(Chisq = 7.655, df = 3, p = 0.054) 
 
Figure 1 clearly illustrates that the HIV negative, non-substance using group (HIV-/SU-), had 
the highest level of self-reported psychotropic medication compliance (54.10%). This group 
was followed closely by the HIV positive non-substance using group (45.46%). The triple 
diagnosis group was the second most poorly adherent subgroup (20%). What emerged during 
the analysis was that the (HIV-/SU+) i.e. the ‘dual diagnosis group’, had the lowest self-
reported level of psychotropic medication compliance (0%).It is important to note though that 
there were only 7 participants in this dual diagnosis group. 
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We subsequently tested bivariate predictors of psychotropic adherence, after excluding 
participants receiving injectable medication (N = 4) and those who were not receiving 
psychotropic medication (N = 1). 
 
Table 2 Association of demographic & clinical variables with psychotropic adherence 
 Adherent  
(N = 50) 
Non-adherent  
(N = 72) 
Test 
Age 43.70 (10.43) 42.83 (9.19) t = 0.474, p: 0.637 
Education  
(% completing high school) 
17 (34.8%) 9 (12.5%) Chisq=8.134, p=0.004 
Income (% greater than R2000 
per month) 
25 (50.00%) 27 (37.50%) 
Chisq =1.855, p=0.170 
 
Stable relationship (%) 16 (32%) 
 
43 (59.72%) 
 
 
Chisq =9.081, p=0.003  
Has children (%) 37 (74%) 65 (90.28%) Chisq =5.705, p =0.017 
% employed or in school 
(full/part time) 
8 (16%) 8 (11.1%) 
Chisq = 0.619, p = 0.431 
Multiple admissions (%) 20 (40%) 27 (37.2%) Chisq = 0.353, p= 0.552 
Hazardous drinking (%) 27 (54.29%) 64 (88.24%) Chisq = 6.972, p= 0.008 
100% ARV adherent*  15 (93.75%) 10 (75%) Odds ratio = 7.045, p = 0.083 
 
*Fishers exact test comparing proportion of 31 seropositive individuals in sample self-reporting 100% ARV  
  compliance by psychotropic medication compliance 
 
As evident in Table 2, lower levels of education (not completing High School); being in a 
stable relationship; having children; and hazardous drinking was significantly associated with 
psychotropic medication non-adherence in our study sample. In other words, psychotropic 
medication adherent participants were more likely to have completed high school and not be 
in a stable relationship. They were also found to be less likely to have children when 
compared to the non-adherent group. They were also slightly more likely to be employed 
(16% versus 11.1%). The largest discrepancy between the adherent and the non-adherent 
group related to the extent of self-reported hazardous drinking (AUDIT score >8). The 
proportion of fully adherent hazardous drinkers was 54.29% compared to non-adherent 
hazardous drinkers (88.24%). 
 
A Fisher’s exact test was conducted to compare the proportion of PLHIV and SMI who 
reported 100% ARV compliance, versus those who were not fully compliant to their ARV 
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regimen. It was found that 93.75% of these individuals who reported being adherent to their 
psychotropic medication, were also reporting full adherence to their ARVs. In comparison, 
only 75% of those individuals who were not fully adherent to their psychotropic medication 
reported full adherence to their ARVs. In other words, psychotropic adherence was associated 
with a higher likelihood of ARV adherence. 
 
The third and final aspect of our study was to determine whether substance use and HIV 
infection separately predict poorer medication compliance. We had postulated that their 
combination in the form of a triple diagnostic group will be particularly prognostic of poor 
levels of medication adherence (both psychotropic and where applicable, ART). To identify 
which of these variables uniquely predicted adherence, a logistic regression model was 
subsequently tested. The results of this regression model are presented in Table 3. 
 
Table 3 Results of linear model of predictors of psychotropic adherence 
 Beta 
coefficient 
Std. Error Z value 
Odds ratio P value 
Hazardous drinking -1.2694      0.8149   -1.558    0.284 0.119 
Education (Grade 12 
+ tertiary) 
1.1998      0.5106    2.350    
3.319 0.019 
Stable relationship -1.0112      0.4288   -2.358    0.364 0.018 
Has children -0.6322     0.5606   -1.128    0.531 0.260 
 
From Table 3 above, it emerged that hazardous drinking did not survive as a predictor of 
psychotropic adherence, after adjusting for education, being in a stable relationship, and 
having children (p value 0.119). On the other hand, after controlling for hazardous drinking; 
relationship status and having children, a participant who had completed high school was 
3.32 times more likely to be adherent (p value 0.019). We further noted that individuals who 
were married or in a long-term relationship were roughly a third as likely to be adherent, after 
adjusting for the other covariates. In other words, being in a stable relationship was 
associated with poorer psychotropic medication adherence. 
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Discussion  
 
In this cross-sectional survey, we report a prevalence of a triple diagnosis in a primary care 
mental health clinic (SMI+ HIV+ hazardous drinking) of 7.9%. There are few studies that we 
can directly compare our findings to. One study conducted in a group of dually diagnosed 
inpatients at a New York centre noted the prevalence of a triple diagnosis to be 23% (27). 
Key differences between that population and ours were that the sample was predominantly 
male, while our study only included females. The review article conducted by Klinkenberg et 
al reported that within a group of people living with a mental illness, 20% to 50% will have a 
comorbid substance use disorder. Conversely, 50% to 75% of people with a substance use 
disorder meet the criteria for a psychiatric disorder (19). Their findings regarding the 
comorbidity range of mental illness and substance use disorders is higher that our own 
findings of a prevalence of 13.4%. Notably though, we mainly assessed hazardous alcohol 
use as opposed to all substances. Their sample consisted of men and women as opposed to 
our population of women only. 
 
An interesting outcome from our analysis was in relation to the triply affected group. We had 
predicted that this group would have the worst outcomes in terms of medication adherence to 
both psychotropic medication and ART where applicable. Our findings did not support our 
initial hypothesis. Women with a triple comorbidity were more adherent (20%) to 
psychotropic medication than those with a dual diagnosis of SMI and hazardous alcohol 
(0%), although overall these are still low levels of adherence. One postulation for this finding 
is that participants who are on ART are already accustomed to taking medication. 
 
Women in resource-limited settings such as in South Africa vulnerable to HIV infection, as 
well as to the psycho-social effects of poverty, gender inequality and violence. Unequal 
power balances related to gender have been reported to be a contributing factor in increasing 
HIV infection risk amongst women (8). In our sample, 55 out of the total 127 women were 
HIV infected (43.3%). This figure is markedly higher than the SA National HIV prevalence 
of 14.4% for women (6). It is also higher than the 13% HIV co-infection prevalence that was 
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reported in a female psychiatric inpatient population at Cecelia Makiwane Hospital (28).   
This figure is notably higher than the Western cape province survey prevalence for women 
aged 20-49, where the prevalence ranged from 17-36% (6).  
 
A United States based review reported an HIV seroprevalence range between 4.0% to 22.9% 
amongst people living with an SMI (29). This range is also much less than our findings. 
There are several possible reasons for this high prevalence. Firstly, we conducted a cross-
sectional study, we are thus unable to ascertain a temporal relationship between the different 
diagnoses. Thus, several these participants may primarily have been diagnosed with HIV and 
developed a SMI secondary to the HIV diagnosis. Secondly, in our setting HIV testing is 
commonly done as part of the initial medical investigations for a patient presenting with signs 
and symptoms of mental illness. This group may thus have had an increased likelihood of 
being tested for HIV due to their SMI status. In resource-rich settings, the prevalence of HIV 
among SMI is estimated to be more than 10 times that of the background community 
prevalence (29). 
 
 A Brazilian National multicentre clinic based study of assessing HIV risk behaviour found 
the following: patients who were married; of older age; female gender; had multiple partners 
and living with children or partners only and those with mild psychiatric diagnoses, were 
more likely to engage in risky sexual practices (30). Brazil is an appropriate country for 
comparison, it has a socioeconomic context that is similar to that of South Africa. Both 
countries are classified as ‘developing nations’(31). Anecdotally the female patients who 
presented for their follow-up appointments at Gugulethu psychiatric clinic, regularly reported 
psychosocial stress related to amongst other factors; verbal and physical abuse from their 
intimate partner commonly fuelled by alcohol use. One can infer that this abuse may extend 
to coercive methods with regards to sexual relations and consequently result in an increased 
risk of contracting HIV. 
 
The classic ‘dual diagnosis’ group of patients who have both SMI and comorbid hazardous 
alcohol use (HIV-/SU+), was found to have the lowest overall level of self-reported 
psychotropic medication adherence (0%). It is important to note though that there were only 7 
participants in this dual comorbidity group. Psychotropic medication adherence was found to 
be 20% in the triple comorbidity group. Hazardous drinking was therefore associated with 
poorer psychotropic medication adherence in our study. This finding is consistent with results 
from the literature we reviewed. 
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A study conducted in the USA amongst a group of 2770 HIV positive women between the 
year 1995 and 2006, reported that 14%–24% of those women met the criteria for hazardous 
drinking (32). This prevalence rate is 2 to 3 times greater than the 7.9% of women found to 
have a triple comorbidity in our study. However, our cohort of women all had a diagnosis of 
an SMI at baseline unlike those in this USA study who only had a baseline diagnosis of HIV. 
What this USA study highlights is the high level of hazardous drinking in a population of 
HIV positive females. They went on to describe the profile of these women at baseline. This 
group of women had a greater likelihood of being older than 40 years of age; be unemployed; 
not have completed high school and have higher levels of symptoms of depression. They 
were also more likely to smoke cigarettes and to use other substances (32). This profile is in 
keeping with our own findings in terms of average age, education levels and employment 
status. 
 
Our study further found that HIV positive, substance using participants were more likely not 
to be on ARVs than their non- substance using HIV-positive counterparts. These findings are 
in keeping with those of Kader and colleagues (16). They screened a cohort of HIV positive 
participants attending HIV clinics in Cape Town for problematic substance use. Their results 
showed that harmful substance use (which included alcohol) was a predictor of ART non-
adherence. This was subsequently associated with a reduction in CD4 count and accelerated 
disease progression (16).This finding of poorer ART adherence amongst substance using 
participants is similar to our own study results.  
 
 
There were several limitations to our study. Firstly, we did not use random sampling 
methods. We used a combination of a sequential and convenience sampling approach. Our 
sampling method limits the extent to which we can generalise our findings to the general 
population. Convenience sampling also tends towards introducing bias into a sample (33). 
One manner in which this bias may manifest is in our findings. Our results may be skewed as 
a consequence of regular clinic attendees being the ones who are also more likely to be 
adherent to their treatment as opposed to non-regular attendees. Secondly, we did not have an 
objective measure of HIV status, relying instead on patient recall and folder review. There is 
a potential risk that some respondents who reported being HIV negative might have 
seroconverted since they last tested. The respondents could also have been in the ‘window 
period’ at the time of testing and thus obtained a falsely negative result on that basis. Our 
total sample size of 127 participants was also relatively small. This has probable implications 
for the power of our study (34). Thirdly, we relied on self-reported medication adherence, 
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rather than an objective measure. This method is likely an under-estimate of non-adherence. 
Self-report measures are prone to recall bias and are influenced by “social desirability” (35). 
Despite these limitations, we propose that our findings meaningfully add to the existing 
literature relating to our initial research question. 
 
Conclusion 
 
In this study, we were not able to confirm that female SMI patients with dual comorbidities 
of hazardous alcohol use and HIV infection, are less adherent than SMI patients who are 
either HIV positive or who use alcohol in a hazardous manner. Instead, our findings suggest 
that hazardous drinking on its own is a risk factor for poorer psychotropic and HIV 
medication adherence in this SMI population.  
 
We thus recommend that an emphasis should be placed on integrated substance abuse and 
mental health programmes at a primary care level. Future studies should consider focusing on 
the causal nature of the relationship between substance use and treatment adherence for both 
psychotropic and ARV interventions in patients with SMIs. 
 
In principle, brief interventions; training in motivational interviewing and access to out-
patient alcohol rehabilitation are critical to the holistic care of patients living with a SMI. 
These programmes should also include providing information to patients with a SMI about 
their increased risk of both HIV infection and substance abuse. A systematic review assessing 
HIV/Alcohol risk reduction strategies in Sub-Saharan Africa, concluded with the 
recommendation that alcohol risk reduction strategies need to be integrated into current HIV 
prevention programmes (36). The high prevalence of HIV co-infection in our SMI 
population, supports the necessity of offering voluntary counselling and testing for HIV in 
people living with a severe mental illness on a regular basis. Potential and actual barriers to 
accessing care should also be addressed as these barriers impact on levels of medication 
adherence amongst outpatient populations.  
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Appendices 
 
Appendix 1 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
PRINCIPAL INVESTIGATOR: Dr Lihle Mgweba    CONTACT NUMBER: 021-370 
1111 
ADDRESS: Valkenberg Hospital, Observatory Road, Observatory Cape Town 7925 
SUPERVISOR: Professor John Joska 
You are being interviewed today in order to find out if you have any alcohol related problems 
and other social problems which may affect your health. This is part of the care you receive at 
this clinic. We would like to use the information you give us to study the problems that 
people with a serious mental illness might have. It will be kept private and not linked to your 
name. We plan to speak to female patients who have a diagnosis of a serious mental illness. 
You should feel free not to answer any question you are uncomfortable with. We would like 
you to sign this page to say that you allow us to use this information, but you are free NOT 
to. This will not affect your care and treatment in any way. It remains between you and the 
interviewer. 
 
 This study received approval by the Research Ethics Committee of the Faculty of Health 
Sciences of the University of Cape Town.  
 
Please answer the questions as honestly as possible. If it is found that you have an alcohol 
problem, the researcher will arrange for you to have any treatment you need, and arrange a 
referral to a rehabilitation centre where appropriate. This will help you in your overall 
treatment. Some people may be asked to go to a special clinic for treatment if they have a 
complicated problem. We will discuss this with you if it happens. 
 
Namhlanje uzakubuzwa imibuzo emayelene nokusebenzisa kwakho kwotywala kunye neminye 
imibuzo emayelene nokuhlala kwakho nezidingo zakho.Oku kudibene noncedo olufumanayo 
apha eclinic.Sifuna ukusebenzisa lencazelo usinika yona ukuze siqondisise ingxaki abantu 
abanokuphazamiseka ngokwengqondo abanazo.Izinto ozithethayo zizohlala ziyimfihlelo 
kwaye akuzusetyenziswa igama lakho.Sizothetha nabantu abangamabhinqa abanesigulo 
sokuphazamiseka ngokwengqondo.Sicela ukhululeke ukuba ungaphenduli imibuzo 
ongabaweliyo ukuyiphendula.Sicela utyikitye eliphepha ukubonisa ukuba uyasinika imvume 
56 
 
yokuba singathetha nawe kodwa ukuba awufuni ungala.Lonto ayizukutshintsha indlela 
ophathwa ngayo apha eclinic.Ukungavumi kwakho kuyakuhlala phakathi kwakho nalomntu 
ebezakubuza lemibuzo. 
Sicela uphendule lemibuzo ngokunyaniseka.Ukuba ufunyaniswe unegxaki 
yotywala,sizakudibanisa nendawo ezinceda abantu abanengxaki yotywala.Oku kuzokunceda 
wena ekunyangweni kwakho.Abanye abantu basenokucelwa ukuba bathunyelwe kwenye 
iclinic kwisibhedlele esikhulu ukuba kubonwa ukuba ingxaki yabo inobuzaza.Sizakuthetha 
nawe ukuba oku kuye kwenzeka. 
 
Patient: “I understand what this interview is about and agree that the information may be 
used to study alcohol related and other problems in people with HIV and mental illness”  
Isigulane: “Ndiyayiqonda ukuba yemibuzo ndizakuyibuza imayelane nantoni kwaye 
ndiyavuma ukuba isetyenziswe ukufunda ngabantu abanengxaki notywala nezinye ingxaki 
ezidibene nokuphazamiseka ngokwengqondo nesifo sengculaza” 
Signed at (place) ......................…........…………….. on (date) …………....……...20__. 
......................................................................   ...................................................................  
Signature of participant Signature of witness 
Investigator/nurse/counsellor: “I have explained this study to the patient in a way that they 
understand and allowed them to ask questions” 
I (name) ……………………………………………..……… declare that: 
 
......................................................................  ……………………….. 
Signature of investigator Signature of witness 
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Appendix 2 
Demographics 
 
a) Today’s Date ______________ (mo/day/4-digit year) 
 
b) Date of Birth  _____/____/____ (mo/day/4-digit year) 
 
1. Age (in years) at point of interview ______________ 
 
Please tik the appropriate box or boxes 
2. Province of origin (where were you born?) 
             1.  Eastern Cape 
             2.  Western Cape 
             3.  Kwazulu Natal 
             4.  Gauteng 
             5.  Other, please specify ______________ 
 
3. Education Level 
Please indicate your highest or current education level 
   1.   Below grade three (Standard one) 
2.    Partial primary school (Grade four to seven/Standard two to five) 
3.    Partial high school  
4.    Passed Matric 
5.    Partial college/University 
6.    College/University graduate  
 
4. Finances – What is the estimated total monthly income in your household 
           1.  Less than R500 
                                2.  R501 – R1500 
                                3.  R1501 – R2000 
                                4.  R2001 – R3000 
                                5.  R3001 – R5000 
                                6.  More than R5000 
 
5.  Relationship Status 
1.  Married or living with someone as if married 
2.  Non-cohabiting relationship (in a relationship but we do not live together)  
3.  Single 
4.  Divorced or separated 
5.  Loss of long-term partner/widowed 
 
6.   Do you have children? 
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0.    No 
 1.   Yes 
If YES, number of children: ___________ 
7. Please indicate who (if anyone) you live with (you may check more than one    
    box) 
1.  Self 
2.  Partner/Spouse 
3.  Extended family 
4.  Children 
5.  Group home / residential treatment 
6.  Other- Please specify: ___________________ 
 
8. Work /School: Please check all that apply to you: 
1.  Full time work 
2.  Part time work  
3.  Full or part time in school 
4.  Neither work nor in school 
5.  On disability 
6.  Other- Please specify: ___________________ 
 
9. Do you know your HIV status? 
               1.  Yes 
               2.  No 
              
10. Are you on ARVS 
             1.  Yes 
             2.  No 
            3.  Not applicable 
 
11. What is your diagnosis (mental illness) 
             1.  Schizophrenia 
             2.  Major depressive disorder 
             3.  Schizoaffective disorder 
             4.  Bipolar disorder 
             5.  I do not know 
             6.  Other, please specify________________ 
 
12. How many admissions have you had to a psychiatric hospital?  
          1.  None 
          2.  One 
          3. Two 
          4. Three to Six 
          5.  Seven to Ten 
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          6. More than Ten 
 
13. Which of the following substances have you used on more than one     
      occasion in the past: 
1.  Cigarettes/tobacco 
2.  Alcohol 
3.  Cannabis 
4.  Methamphetamine (tik) 
5.  Mandrax 
6.  Other, please specify__________________ 
 
14. Which of the following substances are you currently using (used within the  
       last week) 
1.  Cigarettes/tobacco 
2.  Alcohol 
3.  Cannabis 
4.  Methamphetamine (tik) 
5.  Mandrax 
6.  Other, please specify__________________ 
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Appendix 3 
Adherence Self Assessment Instrument 
Instructions for 
Patient: 
Put an "X" on the line below at the point showing your best guess about 
how much of each drug you have taken in the last 3 to 4 weeks. 
0% means you have taken none of the drug 
50% means you have taken half of the drug 
100% means you have taken every single dose of the drug 
DRUG A: 
 
DRUG B: 
 
DRUG C: 
 
DRUG D: 
 
 
Adapted from Machtinger EL, Bansberg DR. Adherence to HIV Antiretroviral Therapy. HIV 
InSite, May 2005. Available online at hivinsite.ucsf.edu.  
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Appendix 4 
Morisky Scale to Assess Adherence to Psychotrophic Medications: Dichotomous 
Response Options (Modified) 
Subjects were asked: 
"Thinking about the medications PRESCRIBED to you by your doctor(s), please answer 
the following questions." 
 NO YES 
Do you ever forget to take your medications?   
Are you careless at times about taking your medications?   
When you feel better, do you sometimes stop taking your medications?   
Sometimes if you feel worse when you take your medications, do you stop 
taking them? 
  
 
Adapted from Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a 
self-reported measure of medication adherence. Med Care 1986;24:67-74.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
Appendix 5 
AUDIT questionnaire: screen for alcohol misuse 
1. How often do you have a drink containing alcohol? 
· Never 
· Monthly or less 
· 2-4 times a month 
· 2-3 times a week 
· 4 or more times a week 
2. How many standard drinks containing alcohol do you have on a typical day when  
drinking? 
· 1 or 2 
· 3 or 4 
· 5 or 6 
· 7 to 9 
· 10 or more 
3. How often do you have six or more drinks on one occasion? 
· Never 
· Less than monthly 
· Monthly 
· Weekly 
· Daily or almost daily 
4. During the past year, how often have you found that you were not able to stop  
drinking once you had started? 
· Never 
· Less than monthly 
· Monthly 
· Weekly 
· Daily or almost daily 
5. During the past year, how often have you failed to do what was normally expected  
of you because of drinking? 
· Never 
· Less than monthly 
· Monthly 
· Weekly 
· Daily or almost daily 
6. During the past year, how often have you needed a drink in the morning to get  
yourself going after a heavy drinking session?2 
· Never 
· Less than monthly 
· Monthly 
· Weekly 
· Daily or almost daily 
7. During the past year, how often have you had a feeling of guilt or remorse after  
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drinking? 
· Never 
· Less than monthly 
· Monthly 
· Weekly 
· Daily or almost daily 
8. During the past year, have you been unable to remember what happened the night  
before because you had been drinking? 
· Never 
· Less than monthly 
· Monthly 
· Weekly 
· Daily or almost daily 
9. Have you or someone else been injured as a result of your drinking? 
· No 
· Yes, but not in the past year 
· Yes, during the past year 
10. Has a relative or friend, doctor or other health worker been concerned about your  
drinking or suggested you cut down? 
· No 
· Yes, but not in the past year 
· Yes, during the past year 
Scoring the audit 
Scores for each question range from 0 to 4, with the first response for each question  
(eg never) scoring 0, the second (eg less than monthly) scoring 1, the third (eg  
monthly) scoring 2, the fourth (eg weekly) scoring 3, and the last response (eg. daily  
or almost daily) scoring 4. For questions 9 and 10, which only have three responses,  
the scoring is 0, 2 and 4 (from left to right). 
A score of 8 or more is associated with harmful or hazardous drinking, a score of 13  
or more in women, and 15 or more in men, is likely to indicate alcohol dependence. 
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Ukuba nguEWE, impendulo nceda phendula le mibuzo ilandelayo – IMIBUZO A1-A10 
NGEZANTSI, OKANYE KE YIYA KU MBUZO 320 
THE AUDIT 
A1.  Usisela kangaphi isiselo esinxilisayo? 
 
 Andizange                   Kanye ngenyanga                2- 4 enyangeni                     2 - 3 evekini               
 4 okanye ngaphezulu ngeveki 
A2.  Zingaphi iziselo oziselayo ezinxilisayo ngosuku nje olulodwa xa uziselela?  
 
1 okanye 2           3 okanye 4              5 okanye 6            7 ukuya ku 9          10 okanye ngaphezulu 
A3.  Ingaba ukhe uthababathe iziselo ezithandathu okanye nangaphezulu ngelixa elinye? 
 
 Andizange              Andikhange kulenyanga iphelileyo                 Ngenyanga                      Ngeveki  
 Yonk’ imihla okanye phantse yonk’ imihla 
A4.  Ingaba kukangaphi kulo nyaka uphelileyo ufumanise ukuba awukwazi ukuyeka ukusela xa sele 
uqalile? 
 
  Andizange           Andikhange kulenyanga iphelileyo                  Ngenyanga                       Ngeveki  
 Yonk’ imihla okanye phantse yonk’ imihla 
A5.  Ingaba kukangaphi kulo nyaka uphelileyo ufumanise ukuba awuphumeleli ekwenzeni izinto 
omele okanye ekulindeleke ukuba uyazenza kodwa ungakwazi ngenxa yokusela kwakho? 
 
  Andizange           Andikhange kulenyanga iphelileyo                  Ngenyanga                       Ngeveki  
 Yonk’ imihla okanye phantse yonk’ imihla 
A6.  Ingaba kukangaphi kulo nyaka uphelileyo ufumanise ukuba ufuna utywala ukuze uqale usuku 
lakho emveni kosuku olunzima lentselo? 
 
  Andizange           Andikhange kulenyanga iphelileyo                  Ngenyanga                       Ngeveki  
 Yonk’ imihla okanye phantse yonk’ imihla 
A7.  Ingaba kukangaphi kulo nyaka uphelileyo ufumanise ukuba uziva unesazela okanye 
umvandedwa emva kokuba usele? 
 
  Andizange           Andikhange kulenyanga iphelileyo                  Ngenyanga                       Ngeveki  
 Yonk’ imihla okanye phantse yonk’ imihla 
65 
 
 
 
A8.  Ingaba kukangaphi kulo nyaka uphelileyo ufumanise ukuba awukwazi ukukhumbula into 
ibiyenzekile ngobusuku obudlulileyo ngenxa yokusela kwakho? 
 
  Andizange           Andikhange kulenyanga iphelileyo                  Ngenyanga                       Ngeveki  
 Yonk’ imihla okanye phantse yonk’ imihla 
A9.  Ingaba wakha wonzakala okanye kwabakho ubani othe wonzakala ngenxa yokusela kwakho? 
 
  Andizange           Andikhange kulenyanga iphelileyo                  Ngenyanga                       Ngeveki  
 Yonk’ imihla okanye phantse yonk’ imihla 
A10.  Ingaba isizalwane okanye isihlobo, okanye ugqirha okanye omnye umntu wezempilo bakha 
bakhathazeka kukusela kwakho okanye bacela ukhe uthothise izinga lokusela? 
 
 Hayi               Ewe, kodwa hayi lo nyaka nje                        Ewe kulo nyaka 
320  Kwezi nyanga ziyi 12 zidlulileyo, ingaba ukhe 
wathabatha iziyobisi ezingezinye ngaphandle 
kotywala, ukuze uzive ungcono okanye utshintshe 
indlela oziva ngayo? 
 
 Ewe        Hayi      Andivumi kuphendula 
UKUBA NGU EWE, nceda cacisa ukuba zeziphi 
iziyobisis obukhe wazisebenzisa  
 
 Marijuana (intsangu, weed, ganja, umya) 
 Cocaine (mandrax, pills) 
 Inhalants (glue, poppers, ebenzine, 
epetroli) 
 Narcotics (heroin, morphine, opium) 
 Stimulants (speed, ecstasy, “8-hour 
pills”) 
 Sleeping, stress pills, depression pills 
 Other 
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